Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT00202345




Registration number
NCT00202345
Ethics application status
Date submitted
15/09/2005
Date registered
20/09/2005
Date last updated
5/05/2015

Titles & IDs
Public title
Iron Sucrose in Stage 3/4 Kidney Disease
Scientific title
Assessment of the Use of Intravenous Iron Sucrose to Maintain Haemoglobin Levels and Delay the Onset of Use of Erythropoietic Agents and/or Dialysis in Stage 3/4 Chronic Kidney Disease
Secondary ID [1] 0 0
Iron Sucrose 61864
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Kidney Failure 0 0
Anemia 0 0
Condition category
Condition code
Renal and Urogenital 0 0 0 0
Kidney disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Iron sucrose

Treatment: Drugs: Iron sucrose
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
The primary endpoint will be the change in Hb concentration at 12 months or termination (dialysis, commencement of an ESA). Minimum permitted enrolment is 6 months.
Timepoint [1] 0 0
Secondary outcome [1] 0 0
The secondary endpoints will be the change in renal function (calculated creatinine clearance), the quality of life, the time taken to dialysis, the time from randomization to the requirement of an ESA and the number of hospitalization days.
Timepoint [1] 0 0

Eligibility
Key inclusion criteria
1. Initial Hb concentrations = 110g/L (males and females)

2. Calculated GFR = 35mL/min (= 50mL/min for diabetics)

3. Demonstration of a clinically significant rise in creatinine and/or a drop in Hb
concentration in the previous 18 months. If such data are not available, the
investigator will make a decision regarding eligibility based on the clinical
circumstances.
Minimum age
18 Years
Maximum age
80 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Age > 80

2. Pregnancy*

3. Unstable ischaemic heart disease*

4. Uncontrolled, severe, congestive cardiac failure

5. Haemochromatosis or iron overload* (ferritin >300µg/L and TSAT >25%)

6. Liver failure

7. Myelodysplastic syndromes or monoclonal gammopathies

8. Active malignancy or gastrointestinal bleeding*

9. Persistent sepsis* or significant chronic inflammation (CRP > 25)*

10. Iron deficiency* (Ferritin <30ug/L and Tsat <15%)or other haematinic disorder

11. Active and significant haemolysis*

12. Previous organ transplantation

13. Concurrent or significant past (>6 months) immuno-suppression

14. Adult polycystic kidney disease

15. Current use of an ESA

16. On dialysis *: patients can still be considered eligible after condition is reversed
or treated

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/08/2004
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/02/2007
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Recruitment hospital [1] 0 0
Central Coast Health - Gosford
Recruitment hospital [2] 0 0
Royal North Shore Hospital - St Leonards
Recruitment hospital [3] 0 0
Royal Brisbane & Women's Hospital - Herston
Recruitment hospital [4] 0 0
Monash Medical Centre - Clayton
Recruitment hospital [5] 0 0
The Royal Melbourne Hospital - Melbourne
Recruitment hospital [6] 0 0
Royal Perth Hospital - Perth
Recruitment postcode(s) [1] 0 0
2250 - Gosford
Recruitment postcode(s) [2] 0 0
2065 - St Leonards
Recruitment postcode(s) [3] 0 0
4006 - Herston
Recruitment postcode(s) [4] 0 0
3168 - Clayton
Recruitment postcode(s) [5] 0 0
3050 - Melbourne
Recruitment postcode(s) [6] 0 0
6847 - Perth

Funding & Sponsors
Primary sponsor type
Other
Name
Melbourne Health
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
One of the complications of late stage kidney disease is the development of a low red blood
cell count (anaemia/low haemoglobin concentration). The Australian Commonwealth government
limits funding of medications (called erythropoietic stimulating agents) to those patients
who have already developed anaemia.

There is evidence supporting the beneficial effects of maintaining a higher haemoglobin in
these patients. Higher haemoglobin can delay the onset of dialysis and reduce the development
of heart enlargement. However, the administration of erythropoietic stimulating agents is not
without risk, including a high financial burden, worsening of high blood pressure and a rare
complication called pure red cell aplasia.

Previous studies have shown that patients with chronic kidney disease require additional iron
to maintain the production of red blood cells. Thus it would be timely to determine if the
administration of iron sucrose to these patients can maintain a near normal haemoglobin
concentration, without the need to start an erythropoietic stimulating agent and possibly
delaying dialysis.

Study Hypothesis: That administration of iron sucrose is superior to standard care in the
prevention of anaemia in patients with stage 3 /4 kidney disease.
Trial website
https://clinicaltrials.gov/ct2/show/NCT00202345
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Lawrence P McMahon, MD
Address 0 0
Melbourne Health
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT00202345